OMERS ADMINISTRATION Corp Makes New $578,000 Investment in Delcath Systems, Inc. (NASDAQ:DCTH)

OMERS ADMINISTRATION Corp acquired a new stake in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 48,000 shares of the company's stock, valued at approximately $578,000. OMERS ADMINISTRATION Corp owned approximately 0.15% of Delcath Systems as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in DCTH. Principal Financial Group Inc. increased its stake in Delcath Systems by 28.8% in the fourth quarter. Principal Financial Group Inc. now owns 115,183 shares of the company's stock valued at $1,387,000 after acquiring an additional 25,736 shares during the period. Baader Bank Aktiengesellschaft bought a new position in shares of Delcath Systems during the 4th quarter worth approximately $204,000. Barclays PLC acquired a new stake in Delcath Systems in the 3rd quarter valued at $104,000. Private Advisor Group LLC acquired a new position in Delcath Systems during the fourth quarter worth $153,000. Finally, Simplify Asset Management Inc. bought a new position in shares of Delcath Systems during the fourth quarter valued at $205,000. Institutional investors and hedge funds own 61.12% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright increased their target price on shares of Delcath Systems from $22.00 to $24.00 and gave the stock a "buy" rating in a research report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $22.75.

Delcath Systems Stock Performance

Shares of DCTH stock opened at $17.10 on Monday. Delcath Systems, Inc. has a 52 week low of $6.33 and a 52 week high of $17.15. The stock has a market capitalization of $595.52 million, a PE ratio of -12.67 and a beta of 0.72. The stock's fifty day moving average is $12.61 and its 200-day moving average is $12.77.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.07). Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. The company had revenue of $19.80 million for the quarter, compared to the consensus estimate of $16.83 million. As a group, analysts forecast that Delcath Systems, Inc. will post -0.79 earnings per share for the current fiscal year.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.